Yazar "Kimyon, Gezmiş" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Behcet Disease With Vascular Involvement Effects of Different Therapeutic Regimens on the Incidence of New Relapses
    (LIPPINCOTT WILLIAMS & WILKINS, 2015) Öner, Fatma Alibaz; Karadeniz, Aslı; Yılmaz, Sema; Balkarlı, Ayşe; Kimyon, Gezmiş; Yazıcı, Ayten; Çınar, Muhammet
    Vascular involvement is one of the major causes of mortality and morbidity in Behcet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only immunosuppressive (IS) agents are recommended. In this study, we aimed to investigate the therapeutic approaches chosen by Turkish physicians during the initial event and relapses of VBD and the association of different treatment options with the relapses retrospectively. Patients with BD (n = 936, female/male: 347/589, mean age: 37.6 +/- 10.8) classified according to ISG criteria from 15 rheumatology centers in Turkey were included. The demographic data, clinical characteristics of the first vascular event and relapses, treatment protocols, and data about complications were acquired. VBD was observed in 27.7% (n = 260) of the patients during follow-up. In 57.3% of the VBD patients, vascular involvement was the presenting sign of the disease. After the first vascular event, ISs were given to 88.8% and AC treatment to 59.8% of the patients. Median duration of AC treatment was 13 months (1-204) and ISs, 22 months (1-204). Minor hemorrhage related to AC treatment was observed in 7 (4.7%) patients. Asecond vascular event developed in 32.9% (n = 86) of the patients. The vascular relapse rate was similar between patients taking only ISs and AC plus IS treatments after the first vascular event (29.1% vs 22.4%, P = 0.28) and was significantly higher in group taking only ACs than taking only ISs (91.6% vs 29.1%, P < 0.001). During follow-up, a third vascular event developed in 17 (n = 6.5%) patients. The relapse rate was also similar between the patients taking only ISs and AC plus IS treatments after second vascular event (25.3% vs 20.8%, P = 0.93). When multivariate analysis was performed, development of vascular relapse negatively correlated with only IS treatments. We did not find any additional positive effect of AC treatment used in combination with ISs in the course of vascular involvement in patients with BD. Severe complications related to AC treatment were also not detected. Our results suggest that short duration of IS treatments and compliance issues of treatment are the major problems in VBD associated with vascular relapses during follow-up.
  • Küçük Resim
    Öğe
    Delay between the onset of psoriasis and arthritis in PsA patients from the PsART international cohort
    (WILEY, 2019) Taşçılar, Koray; Aydın, Sibel Zehra; Akar, Servet; Aksu, Kenan; Bakırcı, Sibel; Bayındır, Ozun; Can, Meryem; Çetin, Gözde; Çınar, Muhammet; Dalkılıç, Ediz; Doğru, Atalay; Erden, Abdulsamet; Ersözlü, Emine Duygu; Erten, Şükran; Kaşifoğlu, Timuçin; Kimyon, Gezmiş; Küçükşahin, Orhan; Omma, Ahmet; Özişler, Cem; Şenel, Soner; Solmaz, Dilek; Tarhan, Emine Figen; Tinazzi, Ilaria; Yavuz, Şule; Yılmaz, Sema; Kalyoncu, Umut
    [Abstract not Available]
  • Küçük Resim
    Öğe
    Impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease
    (WILEY, 2020) Solmaz, Dilek; Bakırcı, Sibel; Kimyon, Gezmiş; Günal, Esen K.; Doğru, Atalay; Bayındır, Özün; Dalkılıç, Ediz; Özişler, Cem; Can, Meryem; Akar, Servet; Çetin, Gözde Yıldırım; Yavuz, Şule; Kılıç, Levent; Tarhan, Emine F.; Küçükşahin, Orhan; Omma, Ahmet; Gönüllü, Emel; Yıldız, Fatih; Ersözlü, Emine D.; Çınar, Muhammet; Al-Onazi, Atallah; Erden, Abdulsamet; Tufan, Müge A.; Yılmaz, Sema; Pehlevan, Seval; Kalyoncu, Umut; Aydın, Sibel Z.
    Objective Psoriatic arthritis (PsA) has a genetic background. Approximately 40% of patients with psoriasis or PsA have a family history of psoriasis or PsA, which may affect disease features. The aim of this study was to assess the effects of family history of psoriasis and PsA on disease phenotypes. Methods Data from 1,393 patients recruited in the longitudinal, multicenter Psoriatic Arthritis International Database were analyzed. The effects of family history of psoriasis and/or PsA on characteristics of psoriasis and PsA were investigated using logistic regression. Results A total of 444 patients (31.9%) had a family history of psoriasis and/or PsA. These patients were more frequently women, had earlier onset of psoriasis, more frequent nail disease, enthesitis, and deformities, and less frequently achieved minimal disease activity. Among 444 patients, 335 only had psoriasis in their family, 74 had PsA, and 35 patients were not certain about having PsA and psoriasis in their family, so they were excluded from further analysis. In the multivariate analysis, family history of psoriasis was associated with younger age at onset of psoriasis (odds ratio [OR] 0.976) and presence of enthesitis (OR 1.931), whereas family history of PsA was associated with lower risk of plaque psoriasis (OR 0.417) and higher risk of deformities (OR 2.557). Family history of PsA versus psoriasis showed increased risk of deformities (OR 2.143) and lower risk of plaque psoriasis (OR 0.324). Conclusion Family history of psoriasis and PsA impacts skin phenotypes, musculoskeletal features, and disease severity. The link between family history of psoriasis/PsA and pustular/plaque phenotypes may point to a different genetic background and pathogenic mechanisms in these subsets.